Deoxycytidine kinase
From Proteopedia
(Difference between revisions)
| Line 11: | Line 11: | ||
The ability of <scene name='54/543346/Cv/4'>DCK to phosphorylate multiple nucleosides arises from the different conformations which the active site glutamic acid can assume</scene> (active site glutamates are in yellow).<ref>PMID:12808445</ref> | The ability of <scene name='54/543346/Cv/4'>DCK to phosphorylate multiple nucleosides arises from the different conformations which the active site glutamic acid can assume</scene> (active site glutamates are in yellow).<ref>PMID:12808445</ref> | ||
| + | |||
| + | == 3D Structures of deoxycytidine kinase == | ||
| + | [[Deoxycytidine kinase 3D structures]] | ||
| + | |||
</StructureSection> | </StructureSection> | ||
== 3D Structures of deoxycytidine kinase == | == 3D Structures of deoxycytidine kinase == | ||
| Line 22: | Line 26: | ||
**[[2no9]], [[2noa]], [[2no0]], [[2no6]], [[2zi9]] – hDCK (mutant) + ADP + chemotherapy agent <br /> | **[[2no9]], [[2noa]], [[2no0]], [[2no6]], [[2zi9]] – hDCK (mutant) + ADP + chemotherapy agent <br /> | ||
**[[2zia]], [[4kcg]] – hDCK (mutant) + UDP + chemotherapy agent <br /> | **[[2zia]], [[4kcg]] – hDCK (mutant) + UDP + chemotherapy agent <br /> | ||
| - | **[[5mqi]], [[5mqt]] – hDCK (mutant) + UDP + dCMP + chemotherapy agent<br /> | + | **[[5mqi]], [[5mqt]], [[5mql]] – hDCK (mutant) + UDP + dCMP + chemotherapy agent<br /> |
*dCK complex with nucleoside | *dCK complex with nucleoside | ||
Revision as of 08:43, 5 June 2019
| |||||||||||
3D Structures of deoxycytidine kinase
Updated on 05-June-2019
References
- ↑ Hazra S, Ort S, Konrad M, Lavie A. Structural and kinetic characterization of human deoxycytidine kinase variants able to phosphorylate 5-substituted deoxycytidine and thymidine analogues . Biochemistry. 2010 Aug 10;49(31):6784-90. PMID:20614893 doi:10.1021/bi100839e
- ↑ Sabini E, Ort S, Monnerjahn C, Konrad M, Lavie A. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol. 2003 Jul;10(7):513-9. PMID:12808445 doi:http://dx.doi.org/10.1038/nsb942
